Toxin and Immunotoxin Based Therapeutic Approaches / / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.

In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied anti...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Place / Publishing House:Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022.
Year of Publication:2022
Language:English
Physical Description:1 online resource (122 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02499nam a2200301 i 4500
001 993562204504498
005 20230225102143.0
006 m o d
007 cr |||||||||||
008 230225s2022 sz o 000 0 eng d
035 |a (CKB)4920000001372300 
035 |a (NjHacI)994920000001372300 
035 |a (EXLCZ)994920000001372300 
040 |a NjHacI  |b eng  |e rda  |c NjHacl 
050 4 |a RC48  |b .T695 2022 
082 0 4 |a 616  |2 23 
245 0 0 |a Toxin and Immunotoxin Based Therapeutic Approaches /  |c edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi. 
264 1 |a Basel :  |b MDPI - Multidisciplinary Digital Publishing Institute,  |c 2022. 
300 |a 1 online resource (122 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 |a Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed February 24, 2023). 
520 |a In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo. 
650 0 |a Clinical medicine. 
776 |z 3-0365-3065-7 
700 1 |a Bolognesi, Andrea,  |e editor. 
700 1 |a Polito, Letizia,  |e editor. 
700 1 |a Bortolotti, Massimo,  |e editor. 
906 |a BOOK 
ADM |b 2023-03-01 01:51:15 Europe/Vienna  |f system  |c marc21  |a 2022-09-22 08:09:39 Europe/Vienna  |g false 
AVE |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338227780004498&Force_direct=true  |Z 5338227780004498  |8 5338227780004498